Survival up after progression in HPV-positive oropharynx CA

Survival up after progression in HPV-positive oropharynx CA

(HealthDay)—For patients with oropharynx cancer (OPC), human papillomavirus (HPV) positivity is associated with improved survival after disease progression, according to a study published online June 23 in the Journal of Clinical Oncology.

Carole Fakhry, M.D., from Johns Hopkins Medical Institutions in Baltimore, and colleagues examined the risk of death after progression for with HPV-positive OPC relative to HPV-negative OPC. Data were collected for patients with stage III to IV OPC, enrolled onto Radiation Therapy Oncology Groups (RTOG) trial 0129 or RTOG 0522. The cohort comprised 181 patients with OPC, including 105 with p16-positive and 76 with p16-negative tumors.

The researchers found that patients with p16-positive and p16-negative tumors had similar patterns of failure and median time to progression. Patients with p16-positive OPC had significantly improved survival rates after a median follow-up of four years, compared with p16-negatve patients (two-year overall survival, 54.6 versus 27.6 percent; median, 2.6 versus 0.8 years; P < 0.001). After adjustment for tumor stage and cigarette pack-years at enrollment, the risk of death after was reduced with p16-positive tumor status (hazard ratio, 0.48) and receipt of salvage surgery (hazard ratio, 0.48) and was increased with distant versus locoregional progression (hazard ratio, 1.99).

"Tumor HPV status is a strong and independent predictor of overall after disease progression and should be a stratification factor for clinical trials for patients with recurrent or metastatic OPC," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry, including Bristol-Myers Squibb, which partially funded the study.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Protein may be key to cancer's deadly resurgences

2 hours ago

Tumor recurrence following a period of remission is the main cause of death in cancer. The ability of cancer cells to remain dormant during and following therapy, only to be reactivated at a later time, frequently ...

US women's awareness of breast density varies

19 hours ago

Disparities in the level of awareness and knowledge of breast density exist among U.S. women, according to the results of a Mayo Clinic study published in the Journal of Clinical Oncology.

Study shows why some brain cancers resist treatment

19 hours ago

Scientists at The University of Texas MD Anderson Cancer Center may have discovered why some brain cancer patients develop resistance to standard treatments including radiation and the chemotherapy agent temozolomide.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.